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Abstract
Background Krukenberg tumor (KT) is a rare secondary ovarian tumor, primarily localized at the gastrointestinal tract in 
most cases. KT is related to severe prognosis due to its aggressiveness, diagnostic difficulties and poor treatment efficacy. 
Several treatments have been used, such as cytoreductive surgery (CRS), adjuvant chemotherapy (CT) and/or hyperthermic 
intraperitoneal chemotherapy (HIPEC). To date, it is still unclear which treatment or combination of treatments is related 
to better survival.
Objective To assess the most effective therapeutic protocol in terms of overall survival (OS).
Methods A systematic review of the literature was performed by searching MEDLINE, Scopus, EMBASE, ClinicalTrial.
gov, OVID, Web of Sciences, Cochrane Library, and Google Scholar for all studies assessing the association of treatments 
with OS in KTs. The effectiveness of each treatment protocol was evaluated by comparing the OS between patients treated 
with different treatment protocols.
Results Twenty retrospective studies, with a total sample size of 1533 KTs, were included in the systematic review. Thera-
peutic protocols used were CRS in 18 studies, CT in 13 studies, HIPEC in 7 studies, neoadjuvant CT in 2 studies, and some 
combinations of these in 6 studies. Seven studies showed that CRS significantly improved OS compared to other treatments 
or association of treatments without it. 11 studies showed that CRS without residual (R0 CRS) had a significantly better OS 
than CRS with residual (R + CRS). Five studies showed that CT significantly improved OS, but other five showed it did not. 
Two studies showed that HIPEC in association with CRS improved OS, while another study showed that efficacy of HIPEC 
was comparable to CT. Two studies evaluated neoadjuvant CT, but results were conflicting.
Conclusion CRS and in particular R0 CRS are the treatments showing the clearest results in improving OS in KT patients. 
Results about CT are conflicting. HIPEC appears effective both alone and in combination with CRS, and also related to fewer 
adverse effect than CT. The usefulness of neoadjuvant CT is still unclear. The association of R0 CRS with HIPEC seems to 
be the most effective and safe therapeutic protocol for KT patients.
Keywords Cancer · Metastasis · Prognosis · Management · oncology · hazard ratio · Therapy
Introduction
Krukenberg tumor (KT) is a rare secondary ovarian tumor 
that represents 1–2% of all ovarian tumors.
The most frequent primary localization is the gastrointes-
tinal tract, while breast and appendix are involved in a minor 
percentage of cases [1, 2].
Not all secondary tumors of the ovary are KT: signet ring 
cells that produce mucin and the sarcomatoid proliferation 
of the stroma are the distinguishing features [3].
KT has a poor prognosis due to its aggressiveness, 
advanced stage, diagnostic difficulties and poor treatment 
efficacy [2, 4].
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Available treatments consist of cytoreductive surgery 
(CRS), adjuvant chemotherapy (CT) and/or hyperthermic 
intraperitoneal chemotherapy (HIPEC), but there is no clar-
ity about which treatment or combination of treatments is 
related to better survival [5–7].
The aim of this study was to assess which treatment or 
combination of treatments may be the most effective in 
terms of increased overall survival (OS) in patients with KT.
Materials and methods
Methods for electronic search, study selection, risk of bias 
assessment and data extraction were defined before the 
beginning of the study.
All stages of the review were conducted independently 
by three reviewers (RL, MDL, AR). Disagreements were 
resolved by consensus among the three reviewers, or among 
all authors if necessary.
The study was reported according to the Preferred 
Reporting Item for Systematic Reviews and Meta-analyses 
(PRISMA) statement [8].
Search strategy
MEDLINE, Scopus, EMBASE, ClinicalTrial.gov, OVID, 
Web of Sciences, Cochrane Library, and Google Scholar 
were used as electronic databases to be searched. Relevant 
articles were searched from the inception of each database 
to August 2018. Several searches were performed using 
combinations of the following text words: “krukenberg”; 
“ovarian”; “ovary”; “ovaries”; “metastasis”; “metastases”; 
“metastatic”; “tumor”; “cancer”; “neoplasm”; “survival”. 
Reference from relevant studies were also assessed.
Study selection
All retrospective or prospective studies assessing the asso-
ciation of treatments with OS in KTs were included.
Exclusion criteria, defined a priori, were sample size < 10; 
case reports; reviews. No language restrictions were applied.
Risk of bias within studies assessment
According to the Methodological Index for Non-Rand-
omized Studies (MINORS) [9], we evaluated the risk of 
bias for each study, in relation to seven domains: (1) Aim 
(i.e. clearly stated aim); (2) Patients (i.e. all patients satis-
fying the criteria for inclusion were included in the study 
during the study period); (3) Data (i.e. data were collected 
according to a protocol established before the beginning of 
the study); (4) Endpoint (i.e. unambiguous explanation of 
the criteria used to measure outcomes); (5) Bias (i.e. the 
study endpoint was assessed without bias); (6) Follow-up 
(i.e. the follow-up was sufficiently long to allow the assess-
ment of the main endpoint), (7) Loss (i.e. no more than 5% 
of patients were lost to follow-up).
The risk of bias was categorized as “low” (criterion met), 
“high” (criterion not met) or “unclear” (data not reported).
Data extraction and analysis
Data from original studies were not modified 
during extraction
Primary extracted data were therapeutic protocols used to 
treat KTs with the related OS. Secondary extracted data were 
country, period of recruitment, sample size, patients’ age, 
primary site of the tumor, treatment side effects.
The effectiveness of each treatment protocol was evalu-
ated by comparing the OS between patients treated with dif-
ferent treatment protocols.
The data analysis was performed using Review Manager 
5.3 (Copenhagen: The Nordic Cochrane Centre, Cochrane 
Collaboration, 2014).
Results
Selection and characteristics of the included studies
Twenty retrospective studies, with a total sample size of 
1533 KTs, were included in the systematic review. The 
whole process of study selection is reported in detail in 
Fig. 1.
Therapeutic protocols used were CRS in 18 studies, CT in 
13 studies, HIPEC in 7 studies, neoadjuvant CT in 2 studies, 
and combinations of these in 6 studies.
Characteristics of the included studies, patients and KTs 
were shown in Table 1.
Risk of bias within studies assessment
About the “Aim”, “Data” and “Endpoints” domains, all stud-
ies were classified at low risk of bias.
About the “Patients” domain, three studies were catego-
rized at low risk of bias [10–12], while 15 at unclear risk 
of bias because they did not clearly specify the inclusion 
criteria [4–7, 13–23]. Last, two studies were classified at 
high risk of bias: one for considering all metastatic ovarian 
tumors as KTs irrespectively of histology [24], and another 
one for lumping together KT and other metastatic ovarian 
cancers [25].
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About the “Bias” domain, nine studies were considered 
at unclear risk of bias, as they did not carry out multivariate 
analysis to confirm results [5, 7, 11, 13, 18, 21–24].
About the “Follow-up” domain, one study was considered 
at high risk of bias due to a follow-up too short in reference 
to the OS to be assessed [7]; while five studies were consid-
ered at unclear risk because they did not specify how long 
the follow-up was [4, 5, 12, 19, 22].
About the “Loss” domain, three studies were categorized 
at low risk of bias, while other three studies at high risk of 
bias because they lost more than 5% of the patients dur-
ing follow-up [5, 11, 12]. The remaining 14 studies were 
considered at unclear risk because they did not specify how 
many patients completed follow-up [4, 7, 10, 13–15, 17–19, 
21–25].
Results about risk of bias for each included study were 
graphically reported in Fig. 2.
Treatments
Seven studies showed that CRS significantly improved OS 
compared to other treatments or association of treatments 
without it [4, 6, 13, 15, 17, 19, 22]. This result was also 
confirmed on multivariate analysis in five studies [4, 6, 15, 
17, 19]. Guzel et al. did not show statistical significance 
about this variable instead [25].
Regarding neoplastic residual, 11 studies showed that 
CRS without residual (R0 CRS) had a significantly better 
OS than CRS with residual (R + CRS) [6, 10–14, 18, 20, 
21, 23, 24]. Six of these studies confirmed the finding on 
multi-variate analysis [6, 10, 12, 14, 20, 24]. By contrast, 
two studies showed no statistical significance about this vari-
able [7, 25].
CT was shown to significantly improve OS at uni- and 
multi-variate analysis in five studies [4, 10, 14, 17, 19]. 
However, other five studies did not show statistical signifi-
cance for this variable [11, 18, 20, 22, 25].
Two articles compared CRS + CT against CT alone [7, 
15]. In one study, CRS + CT showed significantly better OS 
than CT alone [15], while in the other one no significant 
difference was found [7].
The CRS + CT association was also compared with CRS 
alone in two studies [14, 23]. In one study, the CRS + CT 
protocol showed better results at both uni- and multi-variate 
analysis [14]. Instead, the other one found no statistically 
significant differences [23].
Regarding HIPEC, Rosa et  al.  showed that 
CRS + HIPEC + CT had a higher OS compared to CRS + CT, 
and compared to CT alone, on both uni- and multi-variate 
analysis [14]. Furthermore, Wu et  al. showed that the 
CRS + HIPEC had better results than CRS alone, on both 
uni- and multi-variate analysis [16]. Finally, Cheong et al. 
found that there was no significant difference in OS between 
patients treated with CRS + HIPEC and patients treated with 
CRS + CT [22].
Only two studies assessed neoadjuvant CT in relation to 
treatment protocols without it [5, 13]. Among these, Ganesh 
et al. showed a significant lengthening of the OS at uni-
variate analysis, while Seow-En et al. showed no significant 
differences.
Finally, Seow-en et al. found at univariate analysis that 
the execution of the CRS in emergency regimen was related 
to a minor OS compared to its execution in elective regimen.
Results about comparisons amongst OS related to the 
treatment protocols are summarized in Table 2.
Discussion
Main finding and interpretation
Our study pointed out that several different therapeutic pro-
tocols are followed in the treatment of KT. The currently 
available options for treating this neoplasm are CRS, adju-
vant CT, neoadjuvant CT and HIPEC; these treatments may 
be used alone or in combination.
Fig. 1  Flow diagram of studies identified in the systematic review 
[Prisma template (Preferred Reporting Item for Systematic Reviews 
and Meta-analyses)]
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To date, it is still not clear which treatment protocol is the 
most effective one, and the management of patients with KT 
is not standardized.
Cytoreductive surgery
Many studies reported the effectiveness of CRS in length-
ening the OS compared to the absence of such surgical 
treatment [4, 6, 13, 15, 17, 19, 22]. Furthermore, there is 
evidence that a radical CRS, in the absence of residuals 
(R0 CRS), is related to a significant improvement in OS [6, 
10–14, 18, 20–24].
In our study, only two articles showed results contrary to 
these just shown. The first one did not show statistically sig-
nificant OS improvement either for CRS or for R0 CRS, sug-
gesting that the execution of surgery in all its degree of radi-
calness is not advisable [25]. The second one analyzed the 
prognostic value of R0 margins, showing no significant OS 
improvement compared to R + CRS [7]. This discrepancy 
in the results might be partly due to some biases in these 
studies, as already shown in the risk of bias within studies 
assessment. In particular, study by Guzel et al. seemed to be 
affected by a selection bias, not differentiating KTs from all 
other metastatic ovarian tumors in the study sample, while 
results by Kammar et al. seemed to be affected by a follow-
up duration too short to evaluate the efficacy of the treat-
ment. Based on this evidence, it appears deducible that R0 
CRS may be essential in the treatment of KT.
Adjuvant chemotherapy
Regarding CT, results about its impact on OS are conflicting. 
While some studies showed that CT significantly increased 
OS [4, 10, 14, 17, 19], other ones showed opposite results, 
with no significant OS improvement [11, 18, 20, 22, 25].
The efficacy of CT was also evaluated in association with 
CRS in some studies. Two of these studies compared such 
protocol to CT alone [7, 15], and two others to CRS alone 
[14, 23]. However, even in this regard, the results are mixed. 
Compared to CT alone, Cho et al. showed significantly 
longer OS with the CRS + CT protocol, while Kammar 
et al. showed no significant difference. Similarly, compared 
to CRS alone, Rosa et al. showed a significant increase in 
OS for the combined protocol, while Rayson et al. did not 
show significant difference. Given these findings, it seems 
to be not possible to draw any univocal conclusions about 
effectiveness of CT alone or combined with CRS. Thus, 
it might be considerable to spare systemic CT for patients 
with KT, in particular taking account the severe adverse 
effects and performance status worsening associated with 
its administration.
Hyperthermic intraperitoneal chemotherapy
Taking into account the above-mentioned considerations 
on CT, adjuvant therapy with HIPEC might be a good 
compromise. In the literature, only few studies have been 
analyzed HIPEC for KTs patients [14, 16, 22]. Rosa et al. 
assessed the association of HIPEC with CRS and CT. They 
showed that such association significantly increased OS 
more than both CRS + CT protocol and CT alone protocol, 
supporting the independent prognostic value of HIPEC. 
On the other hand, Wu et al. evaluated the effectiveness 
Fig. 2  a Assessment of risk of bias. Summary of risk of bias for each 
study; plus sign: low risk of bias; minus sign: high risk of bias; ques-
tion mark: unclear risk of bias. b Risk of bias graph about each risk 
of bias item presented as percentages across all included studies
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of HIPEC in combination with CRS, showing that this 
association increased the OS about three times on average 
compared to CRS alone. Finally, Cheong et al. investi-
gated the difference about OS between the CRS + HIPEC 
protocol and CRS + CT protocol. They did not show any 
significant difference between the two protocols, conclud-
ing that CT and HIPEC might have the same effectiveness 
if associated with CRS. Despite the low number of studies, 
HIPEC seems to be effective both alone and in combina-
tion with CRS. Furthermore, HIPEC has shown an effec-
tiveness at least equal to CT. Therefore, also given the less 
severe adverse effects compared to CT, HIPEC seems to 
be a preferable adjuvant approach for KT.
Neoadjuvant chemotherapy
Little data have been collected on neoadjuvant CT, which 
seems to be rarely used in KT therapeutic protocols. In the 
literature, only two studies assessed it, showing conflict-
ing results. In particular, Ganesh et al. showed increased 
OS with preoperative chemotherapy, while Seow-En et al. 
did not show statistically significant difference. Therefore, 
there is no sufficient evidence to advocate or discourage 
the use of neoadjuvant CT. However, it appears reasonable 
that neoadjuvant CT might be indicated when R0 CRS is 
not feasible due to the local extension of KT.
Strengths and limitations
To our knowledge, this may be the first systematic review 
about treatments of KT. The study aim was to assess which 
treatment or combination of treatments may be the most 
effective in terms of increased OS. In fact, to date, treat-
ment of KT is not standardized. Despite the rarity of the 
disease, this appears as a serious wealth problem, consid-
ering the poor prognosis of such patients, due to tumor 
aggressiveness, advanced stage, diagnostic difficulties 
and poor treatment efficacy. The low quality of evidence 
about treatment protocols to be followed, partly due to the 
tumor rarity itself, also contributes to the poor prognosis. 
Thus, we tried to improve the quality of evidence, pro-
viding a systematic analysis on a relatively large sample 
(N = 1533).
A limit of our study might be the retrospective design of 
the included studies. Nevertheless, this appears as the only 
possible study design due to the rarity of KT. In fact, pro-
spective trials would be difficult to perform. Another limit 
may be the lack of a multi-variate analysis in some included 
studies. Moreover, the lack of a sufficient number of studies 
that compared the same treatment or combination of treated 
precluded the feasibility of a meta-analysis.
Conclusion
CRS and in particular R0 CRS are the treatments that show 
the clearest results in improving OS in KT patients. Regard-
ing adjuvant CT, results about its effectiveness are conflict-
ing, but it seems that CT cannot replace surgery in a satisfac-
tory way. By contrast, despite being assessed in few studies, 
HIPEC seems to be not only effective both alone and in 
combination with CRS, but also related to fewer adverse 
effect than CT. The usefulness of neoadjuvant CT is still 
unclear, and seems to be advisable only to try a R0 CRS.
Finally, the association of R0 CRS with HIPEC seems to 
be the most effective and safe therapeutic protocol for KT 
patients.
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